Exhibit 99.1
TYME Technologies. Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote FOR Proposed Merger of
Syros and Tyme
BEDMINSTER, New Jersey, September 7, 2022 Tyme Technologies, Inc. (NASDAQ:TYME) (Tyme or the
Company), today announced that independent proxy advisory firms Glass, Lewis & Co. (Glass Lewis) and Institutional Shareholder Services Inc. (ISS) have recommended that Tyme stockholders vote
FOR the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. (Syros) and FOR all other matters to be voted upon at the Companys upcoming Special Meeting of Stockholders (the Special
Meeting) scheduled for September 15, 2022 at 11:00 a.m., Eastern Time.
ISS and Glass Lewis are leading independent, third-party proxy advisory
firms who, among other services, provide proxy voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.
As previously announced, on July 3, 2022, Syros and Tyme entered into an Agreement and Plan of Merger, pursuant to which Tyme will merge with a wholly
owned subsidiary of Syros. In the merger, it is expected that Syros would issue approximately 74.3 million shares of its common stock to Tyme stockholders to acquire Tyme and Tyme stockholders are expected to receive approximately 0.4312 shares
of Syros common stock for each share of Tyme common stock. The actual number of shares to be issued in the merger and the exchange ratio will be subject to adjustment based on the amount of Tymes net cash at closing and the number of Tyme
shares outstanding at closing. Upon closing of the merger, Tyme will become a wholly owned subsidiary of Syros.
Concurrent with the merger, Syros
announced a $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94. New and existing investors in the PIPE which was led by a life sciences-focused investment fund include Syros co-founder and founding investor Flagship Pioneering, Avidity Partners, Deep Track Capital, entities affiliated with Bain Capital Life Sciences, Invus, Samsara BioCapital, Adage Capital Partners LP and Ally Bridge
Group, as well as other investors.
Tymes Board of Directors recommends that you vote FOR the proposed merger.
All Tyme stockholders of record as of the close of business on August 8, 2022 are entitled to vote at the Special Meeting.
Tymes stockholders are reminded that their vote is extremely important, no matter how many shares they own. To follow the recommendations of Glass
Lewis, ISS and Tymes Board of Directors, stockholders should vote FOR the proposed merger and FOR all other matters to be voted upon at the Special Meeting.
About Tyme Technologies, Inc.
Tyme is an emerging
biotechnology company developing cancer metabolism-based therapies (CMBTs) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also
maintaining patients quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, Tymes therapeutic approach is designed to take advantage of a cancer
cells innate metabolic weaknesses to cause cancer cell death.